Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents

被引：1

作者：

Zhang, Michelle Y. Y. ^{[1
]}

Othus, Megan ^{[2
]}

Shaw, Carole ^{[3
]}

Schonhoff, Kelda G. G. ^{[1
]}

Halpern, Anna B. B. ^{[1
,3
]}

Appelbaum, Jacob ^{[1
]}

Hendrie, Paul C. C. ^{[1
]}

Walter, Roland B. B. ^{[1
,3
,4
,5
]}

Estey, Elihu H. H. ^{[1
,3
]}

Percival, Mary-Elizabeth M. ^{[1
,3
,6
]}

机构：

[1] Univ Washington, Dept Med, Seattle, WA USA

[2] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA USA

[3] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA USA

[4] Univ Washington, Dept Lab Med & Pathol, Seattle, WA USA

[5] Univ Washington, Dept Epidemiol, Seattle, WA USA

[6] 825 Eastlake Ave E,MS LG-700, Seattle, WA 98109 USA

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 05期

关键词：

Hypomethylating agent; acute myeloid leukemia; outcomes; high intensity induction; MYELODYSPLASTIC SYNDROME; AZACITIDINE; THERAPY; INDUCTION; RISK; VENETOCLAX; CYTARABINE; EFFICACY; ADULTS;

D O I：

10.1080/10428194.2023.2186732

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with acute myeloid leukemia (AML) who have failed hypomethylating agents (HMA) have a poor prognosis. We examined whether high intensity induction chemotherapy could abrogate negative outcomes in 270 patients with AML or other high-grade myeloid neoplasms. Prior HMA therapy was significantly associated with a lower overall survival (OS) as compared to a reference group of patients with secondary disease without prior HMA therapy (median 7.2 vs 13.1 months). In patients with prior HMA therapy, high intensity induction was associated with a non-significant trend toward longer OS (median 8.2 vs 4.8 months) and decreased rates of treatment failure (39% vs 64%). These results redemonstrate poor outcomes in patients with prior HMA and suggest possible benefit of high intensity induction that should be evaluated in future studies.

引用

页码：990 / 996

页数：7

共 32 条

[1] Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure [J].

Ball, Brian J. ;

Famulare, Christopher A. ;

Stein, Eytan M. ;

Tallman, Martin S. ;

Derkach, Andriy ;

Roshal, Mikhail ;

Gill, Saar, I ;

Manning, Benjamin M. ;

Koprivnikar, Jamie ;

McCloskey, James ;

Testi, Rebecca ;

Prebet, Thomas ;

Al Ali, Najla H. ;

Padron, Eric ;

Sallman, David A. ;

Komrokji, Rami S. ;

Goldberg, Aaron D. .

BLOOD ADVANCES, 2020, 4 (13) :2866-2870

[2] Outcomes After Induction Chemotherapy in Patients With Acute Myeloid Leukemia Arising From Myelodysplastic Syndrome [J].

Bello, Celeste ;

Yu, Daohai ;

Komrokji, Rami S. ;

Zhu, Weiwei ;

Wetzstein, Gene A. ;

List, Alan F. ;

Lancet, Jeffrey E. .

CANCER, 2011, 117 (07) :1463-1469

[3]

Bernard Elsa, 2022, NEJM Evid, V1, pEVIDoa2200008, DOI 10.1056/EVIDoa2200008

[4] A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [J].

Bishop, JF ;

Matthews, JP ;

Young, GA ;

Szer, J ;

Gillett, A ;

Joshua, D ;

Bradstock, K ;

Enno, A ;

Wolf, MM ;

Fox, R ;

Cobcroft, R ;

Herrmann, R ;

VanDerWeyden, M ;

Lowenthal, RM ;

Page, F ;

Garson, OM ;

Juneja, S .

BLOOD, 1996, 87 (05) :1710-1717

[5] The leukemia strikes back: a review of pathogenesis and treatment of secondary AML [J].

Cheung, Edna ;

Perissinotti, Anthony J. ;

Bixby, Dale L. ;

Burke, Patrick W. ;

Pettit, Kristen M. ;

Benitez, Lydia L. ;

Brown, Julia ;

Scappaticci, Gianni B. ;

Marini, Bernard L. .

ANNALS OF HEMATOLOGY, 2019, 98 (03) :541-559

[6] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].

DiNardo, C. D. ;

Jonas, B. A. ;

Pullarkat, V. ;

Thirman, M. J. ;

Garcia, J. S. ;

Wei, A. H. ;

Konopleva, M. ;

Doehner, H. ;

Letai, A. ;

Fenaux, P. ;

Koller, E. ;

Havelange, V. ;

Leber, B. ;

Esteve, J. ;

Wang, J. ;

Pejsa, V. ;

Hajek, R. ;

Porkka, K. ;

Illes, A. ;

Lavie, D. ;

Lemoli, R. M. ;

Yamamoto, K. ;

Yoon, S. -S. ;

Jang, J. -H. ;

Yeh, S. -P. ;

Turgut, M. ;

Hong, W. -J. ;

Zhou, Y. ;

Potluri, J. ;

Pratz, K. W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629

[7] Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia [J].

DiNardo, Courtney D. ;

Lachowiez, Curtis A. ;

Takahashi, Koichi ;

Loghavi, Sanam ;

Xiao, Lianchun ;

Kadia, Tapan ;

Daver, Naval ;

Adeoti, Maria ;

Short, Nicholas J. ;

Sasaki, Koji ;

Wang, Sa ;

Borthakur, Gautam ;

Issa, Ghayas ;

Maiti, Abhishek ;

Alvarado, Yesid ;

Pemmaraju, Naveen ;

Bravo, Guillermo Montalban ;

Masarova, Lucia ;

Yilmaz, Musa ;

Jain, Nitin ;

Andreeff, Michael ;

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Kornblau, Steven ;

Ravandi, Farhad ;

Konopleva, Marina Y. ;

Kantarjian, Hagop M. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) :2768-+

[8] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

[9] Clinical update on hypomethylating agents [J].

Duchmann, Matthieu ;

Itzykson, Raphael .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (02) :161-169

[10] Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure [J].

Duong, Vu H. ;

Lin, Karen ;

Reljic, Tea ;

Kumar, Ambuj ;

Al Ali, Najla H. ;

Lancet, Jeffrey E. ;

List, Alan F. ;

Komrokji, Rami S. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06) :711-715

← 1 2 3 4 →